đź’ŠExclusive Patent License Notice for CAR Technology by NIH
Prospective Grant of an Exclusive Patent License: The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases
Summary
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents applications listed in the Supplementary Information section of this notice to Capstan Therapeutics, Inc. (Capstan), a company located in San Diego, California, the United States of America.
Agencies
- Health and Human Services Department
- National Institutes of Health
Business Impact
$$$ - High
The notice discusses the prospective grant of an exclusive patent license to Capstan Therapeutics, Inc. for the development of CAR technology, indicating potential financial opportunities for businesses engaged in biotech and pharmaceutical sectors. The exclusivity and royalty-bearing nature of the license suggests significant market implications for successful commercialization.